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Abstract 
Background/Aims: Gastrointestinal lesions of Behçet’s disease (BD) are often 
refractory to medical therapy and sometimes result in serious comorbidities, such as 
gastrointestinal perforation and massive bleeding. There are several reports of patients 
with BD comorbid with myelodysplastic syndrome (MDS) involving trisomy 8 that 
frequently have intestinal lesions refractory to conventional medical therapy. Little is 
known about the efficacy of infliximab (IFX) for these intestinal lesions. Methods: We 
present two cases of intestinal BD with MDS involving trisomy 8 who did not respond 
to IFX, and review previous reports of BD with MDS involving trisomy 8 concerning 
their responsiveness to conventional medical therapy. Results: Among 33 previously 
reported cases that received medical treatment for BD, 20 cases (60.6 %) showed 
temporary improvement of the BD symptoms, 10 (30.3 %) deteriorated, and 3 (9.1 %) 
showed no change. Among the 10 showing deterioration, 9 cases had intestinal lesions. 
Our two cases failed to respond to IFX, resulting in a poor prognosis. Conclusions: IFX 
might not be effective for improving intestinal BD comorbid with MDS involving 
trisomy 8. Trisomy 8 is associated with the BD prognosis and refractoriness to 
conventional medical therapy.  
 
Introduction 
 Behçet’s disease (BD), an inflammatory disease of unknown etiology, is 
characterized by recurrent oral ulcerations, genital ulcerations, eye and skin lesions, and 
a positive pathergy test [1]. Gastrointestinal lesions are present in 3% to 26% of BD 
patients and typically form discrete ulcers in the ileocecal area [2]. These 
gastrointestinal lesions are often refractory to conventional medical therapy [3], and 
sometimes cause life-threatening comorbidities such as intestinal perforation and 
massive bleeding [4].  
 Generally, colchicine, 5-aminosalicylic acid (5-ASA), corticosteroids, and 
immunosuppressive agents are used to treat BD. The effect of infliximab (IFX), a 
chimeric monoclonal antibody against tumor necrosis factor (TNF)-α on eye lesions and 
intestinal lesions refractory to conventional medical therapy in BD patients has been 
reported [5-7].  
 Several recent reports described a relationship between trisomy 8 associated 
with MDS and intestinal BD [8-10]. Because trisomy 8 induces the activation of an 
abnormal inflammatory process and immune gene expression [11], trisomy 8 in MDS 
could contribute to the aggravation of intestinal ulcers in patients with BD. In fact, the 
intestinal lesions in BD patients with trisomy 8 are refractory to conventional medical 
therapy. Little is known, however, about the efficacy of IFX for treatment of the 
intestinal lesions of BD patients with trisomy 8.  
 In this report, we present two cases of BD patients with trisomy 8 that received 
IFX for their intestinal lesions and review previous reports of BD patients with MDS 




 In February 2011, a 36-year-old Japanese man visited our hospital with a 
2-month history of oral aphthoid ulcers and intermittent right lower quadrant abdominal 
pain. Laboratory data showed mild leukopenia (white blood cells 2500/µL [normal, 





/µL], hemoglobin 11.2 g/dL [normal, 12.9-17.2 g/dL], mean 
corpuscular volume 92.3 fl [normal, 82-100 fl], mean corpuscular hemoglobin 32.6 pg 
[normal, 27.5-34.5 pg], mean corpuscular hemoglobin concentration 31.8% [normal, 
32-35.5%]), and an elevated C reactive protein level (10.3 mg/dL [normal 0-0.3 
mg/dL]). An abdominal computed tomography scan showed remarkably increased wall 
thickness of the ileocecum. Total colonoscopy revealed a large punched-out ulcer at the 
ileocecal valve and scattered ulcer scars in the terminal ileum. Histologic findings of 
biopsy specimens indicated non-specific inflammation and no granuloma. The patient 
was in an afebrile state and had no eye symptoms, skin lesions, or genital ulcers. A 
serologic test was positive for HLA-B51 allele. Intestinal BD was suspected. A bone 
marrow biopsy performed to further evaluate the continuous leukopenia revealed 
hypocellularity of the bone marrow without an increase of blast cells. Although his bone 
marrow biopsy showed no cellular morphologic changes, cytogenetic analysis 
demonstrated the presence of an abnormal cell line: 47, XY, +8. Abnormal 
chromosomes were found in all 20 cells examined. These findings led to the diagnosis 
of MDS (refractory anemia).  
 Treatment with colchicine and 5-ASA was initiated for BD, but his symptoms 
deteriorated. In addition, despite intravenous corticosteroid administration at 50 mg/day, 
his symptoms did not subside. We started 3 mg/kg of IFX combined with methotrexate. 
This combination therapy was also not effective and the patient required ileocecal 
resection 1 month after starting the combination therapy.  
 
Case 2 
 A 29-year-old Japanese woman was referred to our hospital in 1997 because of 
recurrent oral ulcers and intermittent fever. Physical examination revealed genital ulcers, 
folliculitis-like eruptions, and erythema nodosum. Total colonoscopy showed multiple 
punched-out ulcers located from the terminal ileum to the ascending colon. Based on all 
of these findings, she was diagnosed with intestinal BD.  
 Her symptoms subsided after starting corticosteroid treatment at 60 mg/day. 
She complained of massive melena while reducing the dose of corticosteroid. Increasing 
the corticosteroid dose to 60 mg/day improved her symptoms, and she was maintained 
in a stable condition with less than 10 mg/day of corticosteroids thereafter.  
 In 2005, her laboratory data showed pancytopenia. A bone marrow biopsy 
performed to further evaluate her pancytopenia revealed normoplastic bone marrow 
with dysplasia in all three lineages of bone marrow cells. The rate of blastic cells 
remained at 2.0%. Cytogenetic analysis demonstrated the presence of two cell lines: 47, 
XX, +8 and 46, XX. Of the 20 cells examined, 12 showed an abnormal female 
karyotype with extra 8 chromosomes, and the remaining 8 cells had normal sets of 
chromosomes. These findings led to the diagnosis of MDS (refractory anemia).  
 The patient was treated with 300 mg of oral cyclosporine for MDS, but she 
required repeated transfusions of red blood cells and platelets. In 2006, her BD 
symptoms relapsed with recurrent intestinal ulcers. Her BD symptoms subsided with 
2250 mg/day of 5-ASA and increased corticosteroid (30 mg/day). Despite the additional 
use of immunomodulators, her abdominal pain recurred while tapering the dose of 
corticosteroid. Therefore, we started 5 mg/kg of IFX in August 2007. Administration of 
IFX, however, did not ameliorate her abdominal pain. She had repeated febrile 
neutropenia and then developed septic shock, and died in November 2008.  
 
Characteristics and outcomes of medical treatment in BD patients with MDS 
involving trisomy 8 
 Table 1 summarizes the previous reports of BD patients with MDS involving 
trisomy 8, which was searched using PubMed (date searched: June 1, 2013). We 
collected 41 cases from 29 reports. Of the 41 cases, intestinal ulcers were found in 29 
cases (70.7%). On the other hand, eye lesions were found in only 3 cases (7.3%). Oral 
ulcers, genital ulcers, and skin lesions were found in 36 cases (87.8%), 30 cases (73.2%), 
and 28 cases (68.3%), respectively. Thirty-three cases received medication for their BD, 
two received hematopoietic stem cell transplantation for their MDS prior to the 
treatment for BD, and two received no medical treatment. In four cases, treatment 
outcome for the BD was not described.  
 As a result, 20 cases (60.6%) showed temporary improvement of the BD 
symptoms, 10 (30.3%) deteriorated, and 3 (9.1%) showed no change. Among the 10 
cases that showed deterioration, 9 (90%) had intestinal lesions.  
 
Discussion 
 In the present case series, IFX was not effective for improving intestinal BD 
comorbid with MDS involving trisomy 8, suggesting the possibility that some factors 
other than TNF-α are involved in the pathogenesis of intestinal BD with MDS involving 
trisomy 8. Intestinal lesions of BD are usually refractory to conventional therapy and 
result in life-threatening comorbidities, such as intestinal perforation and massive 
bleeding. Recent reports showed that IFX has beneficial effects on these intractable 
intestinal lesions of BD. Little is known, however, about the effect of IFX in intestinal 
BD comorbid with MDS involving trisomy 8.  
 Trisomy 8 is one of the most frequent abnormalities found in 6.5% to 16.3% of 
primary MDS patients [12]. Furthermore, the prevalence rate of trisomy 8 is as high as 
73.7% in MDS patients with BD [13]. Previous reports revealed several clinical 
characteristics such as a low prevalence rate of eye lesions and a high prevalence rate of 
intestinal lesions in BD patients with MDS involving trisomy 8 [14]. As shown in Table 
1, only 7.3% of BD patients with MDS involving trisomy 8 had eye lesions whereas 
70.7% had intestinal lesions [2, 8-10, 15-34]. These data showed a similar tendency as 
previous reports. We further tried to compare the behaviors of BD between those with 
MDS involving trisomy 8 and those with MDS involving other types of chromosomal 
aberrations. However, in addition to the rarity of BD with MDS, more than 70% of 
these patients had trisomy 8 as described above. Therefore, we could not obtain enough 
information, which could characterize the behavior of BD with chromosomal 
aberrations other than trisomy 8. 
 Chen et al. [11] analyzed the gene expression patterns in hematopoietic 
progenitor cells obtained from MDS patients with monosomy 7 and trisomy 8, and 
detected distinctively higher gene expression of several cytokines, such as IL-6, MCP-1, 
VCAM-1, and ICAM-1, which are involved in immune and inflammation in trisomy 8 
patients. Furthermore, Kimura et al. [9] reported three cases of intestinal BD with MDS 
involving trisomy 8 who developed thrombosis and suggested that trisomy 8 is a risk 
factor not only for intestinal ulceration but also for thrombosis. On the other hand, in 
addition to the local migration of neutrophils stimulated by several cytokines, an 
impaired microbicidal function of neutrophils in MDS [35] might augment dysregulated 
immune response in BD. Thus, increased gene expression of inflammatory cytokines 
and thrombus formation related to trisomy 8, and abnormal functions of neutrophil in 
MDS might contribute to the pathogenesis of intestinal ulcers in BD. Despite the use of 
several therapeutic agents, such as colchicine, 5-ASA, corticosteroids, and 
immunomodulators in the majority of cases, about 30% of BD patients with MDS 
involving trisomy 8 failed to respond to these conventional medical therapies. In 
addition, 90% of those who failed to respond had intestinal lesions.  
 Considering that extensive intramedullary cell death in MDS patients is related 
to TNF-α [36] and that serum TNF-α concentrations are increased in BD patients [37], 
IFX treatment would theoretically be ideal for BD patients with MDS. In one report, an 
intestinal BD patient with MDS involving trisomy 8 was successfully treated with a 
combination of IFX and methotrexate for her intestinal lesion [7]. Both of our cases, 
however, failed to respond to IFX and had a poor prognosis. Thus, the pathogenesis of 
BD with MDS involving trisomy 8 seems to be complicated, and other cytokines and 
chemokines independent of TNF-α or some other factors might be involved. Trisomy 8 
is clearly associated with BD prognosis and refractoriness to conventional medical 
therapy. Therefore, further accumulation of clinical cases is necessary to elucidate the 
pathogenesis of BD with MDS involving trisomy 8.   
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Table1. Reported cases of BD patients with MDS involving trisomy 8
Table 1. 
 
     
     
             




Oral ulcer Genital ulcer Skin lesion Eye lesion intestinal ulcer BD MDS 
Nehashi, 1988 72 M RA + + + - - + S Improved Unchanged 
Nakayama, 1989 57 M RA + + - - + ND S Improved Unchanged 
Takishita, 1991 59 M RAEB + - - + - ND S Death Unchanged 
Yoshizawa, 1992 45 F RARS + + + - - ND S Improved Unchanged 
Chyuma, 1992 41 F RARS + + + - + + M, S Improved Unchanged 
Ito, 1993 45 F RAEB - + - - - ND S Improved Unchanged 
Yano, 1995 23 F RA + + + - + ND S, SASP Improved Unchanged 
Yano, 1996 54 F RA + + + - - - S Improved Death 
Ohno, 1997 34 F RA + + - + + - - Improved Unchanged 
Della Rossa, 1998 50 M RARS + + + - + - M, S, AZA, CsA Improved Death 
Nawata, 1999 59 M RA + + + - - + S Improved Unchanged 
Tanaka, 2000 39 M RA + + - - + - M Improved Unchanged 
Ogawa, 2001 25 M RA + + + - + - S Improved Unchanged 
  41 F RA + + + - + - S Improved Unchanged 
Kimura, 2001 74 F RA + - - - + ND S Death Unchanged 
  36 F RA - - + - + ND S Improved Unchanged 
  31 F RA - - - - + ND SASP, S Death Unchanged 
Fujita, 2002 64 M RA + + - - + - S Operation Unchanged 
Adachi, 2003 28 F RA + + + - + - SASP, M, S Operation Unchanged 
  39 F RA + + + - + - Col, SASP, M, S Operation Unchanged 
Hasegawa, 2003 43 F RA + + + - - - Col, S, AZA, CsA Improved Unchanged 
Tomonari, 2004 27 F RAEB + + + - - + Col, S, HSCT Improved Improved 
Ando, 2005 49 M RA + + - - + ND CsA Unchanged Improved 
Kuttikat, 2005 54 M RA - + + - - - S, AZA Unchanged Unchanged 
Tsubata, 2005 69 M RAEB-t + - + - + + SASP, M, S Deteriorated Death 
Kawabata, 2006 76 F RA + + + - + + SASP Improved Unchanged 
  75 M RAEB + + + - + ND Col, SASP Improved Unchanged 
  67 F RAEB + - - - + ND Col, SASP Deteriorated Death 
Nonami, 2007 28 F RAEB + - - - + - HSCT Improved Improved 
Ahn, 2008 46 F MDS-U + + + - + ND S, AZA Operation ND 
  34 F RA + + + - + ND S, AZA ND ND 
  53 M RCMD + + + - + ND S, AZA ND ND 
  49 F RCMD + + - + + ND S ND ND 
  47 M RAEB + + + - - ND S ND ND 
Fujimura, 2010 71 M RA + - + - - ND Col, S Improved Unchanged 
  74 M RA - - + - - ND Col, S Improved Unchanged 
Tomonari, 2011 4 F ND + - + - + - HSCT Improved Improved 
Iwata, 2011 52 F RARS + + + - + - S, MTX, IFX Improved ND 
Chen, 2012 24 F RA + + + - + ND - Operation ND 
Present cases 36 M RA + - - - + + Col, M, S, MTX, CsA, IFX   Operation Unchanged 
  29 F RA + + + - + - M, S, AZA, CsA, Tac, IFX Unchanged Unchanged 
             
    
oral ulcer genital ulcer skin lesion eye lesion intestinal ulcer 
    
   
N 36 30 28 3 29 
    
   
% (/41) 87.8  73.2  68.3  7.3  70.7  
    
             
             * RA: refractory anemia, RAEB: refractory anemia with excess blasts, RARS: refractory anemia with ringed sideroblasts, RAEB-t: refractory anemia with excess blasts in transformation, MDS-U: 
myelodysplastic syndrome-unclassified, RCMD: refractory cytopenia with multilineage dysplasia, ND: no description, Col: colchicine, SASP: salazosulfapyridine, M: mesalazine, S: corticosteroid, MTX: 
methotrexate, AZA: azathioprine, CsA: cyclosporine, Tac: tacrolimus, IFX: infliximab, HSCT: hematopoietic stem cell transplantation 
 
